Related Experiment Video
Updated: Jan 20, 2026
Reliability and Validity: Consistency, Reproducibility and Accuracy
Abstract:
As immune checkpoint inhibitors are approved for more cancers and indications, researchers continue to hunt for biomarkers that can predict which patients will respond to the therapies. One such biomarker, tumor mutation burden, has potential, but requires better standardization across labs and institutions, as well as stronger prospective clinical trial data, before it can be considered for routine clinical use.
Insights
Tumor mutation burden shows promise as a biomarker for predicting patient response to immune checkpoint inhibitors. However, further standardization and clinical trial data are needed before its routine use.
Area of Science:
- Oncology
- Immunotherapy
- Biomarker Discovery
Background:
- Immune checkpoint inhibitors (ICIs) are increasingly approved for various cancers.
- Identifying predictive biomarkers for ICI response is crucial for personalized medicine.
Related Concept Videos
Reliability and Validity
Data Validation
Nursing assessment guides are generally based on holistic models rather than medical...
Data Validation
Key parameters for method validation include:
Formulating and Validating Nursing Diagnosis II
Risk nursing diagnoses represent clinical judgments of an individual, family, or community more vulnerable to developing the health problem than others...
Formulating and Validating Nursing Diagnosis I
There are thirteen domains...
05:37An R-Based Landscape Validation of a Competing Risk Model

